Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell Signaling in Plants01:25

Cell Signaling in Plants

5.7K
Plant cells communicate to coordinate their cycle of growth, flowering and fruiting, and activities in roots, shoots, and leaves in response to the changing environmental conditions. Plant signaling is distinct from animal signaling. Plants primarily utilize enzyme-linked receptors, whereas the largest class of cell-surface receptors in animals are G-protein coupled receptors (GPCRs). Unlike animals, receptor tyrosine kinases are rare in plants. Instead, plants have a diverse class of...
5.7K
GPCR Desensitization01:12

GPCR Desensitization

6.4K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.4K
Regulation of the Unfolded Protein Response01:31

Regulation of the Unfolded Protein Response

2.6K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.6K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

8.7K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.7K
IP3/DAG Signaling Pathway01:11

IP3/DAG Signaling Pathway

12.4K
Membrane lipids such as phosphatidylinositol (PI) are precursors for several membrane-bound and soluble second messengers. Specific kinases phosphorylate PI and produce phosphorylated inositol phospholipids. One such inositol phospholipids are the  phosphatidylinositol-4,5 bisphosphate [PI(4,5)P2], present in the inner half of the lipid bilayer. Upon ligand binding, GPCR stimulates Gq proteins to turn on phospholipase Cꞵ. Activated phospholipase Cꞵ cleaves PI(4,5)P2 and...
12.4K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

2.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<sup>18</sup>F-fluciclovine positron emission tomography uptake is not exclusive to malignant brain tumors: Two cases of low-grade and benign lesions with detailed pathological findings.

Surgical neurology international·2026
Same author

Crystalglobulin-Induced Nephropathy and Cardiac Nonamyloidotic Immunoglobulin Deposition Disease: A Fatal Case Report.

Kidney medicine·2026
Same author

Technical principles of watertight dural closure in endoscopic endonasal surgery: How I do it.

Acta neurochirurgica·2026
Same author

Interactions between atomic-scale skyrmions in 2D chiral magnets.

Scientific reports·2026
Same author

Complete Remission After Percutaneous Renal Artery Angioplasty for Focal Segmental Glomerulosclerosis due to Takayasu Disease: A Case Report.

Kidney medicine·2026
Same author

Observation of the Einstein-de Haas effect in a Bose-Einstein condensate.

Science (New York, N.Y.)·2026
Same journal

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Prediction of severe oral mucositis in cancer treatment: the role of the oral-gut axis in precision supportive care].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Iron dysregulation and ferroptosis in heart failure: the dual faces of deficiency and overload].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec<sup>®</sup> ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway<sup>®</sup>)].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Oxytocin regulates social familiarity-dependent mate choice in medaka].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
See all related articles

Related Experiment Video

Updated: Sep 9, 2025

A Caenorhabditis elegans Model System for Amylopathy Study
10:33

A Caenorhabditis elegans Model System for Amylopathy Study

Published on: May 17, 2013

10.6K

[Aβ Receptor PirB and its regulation by LOTUS].

Yuki Kawaguchi1, Kohtaro Takei1

  • 1Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine.

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|August 31, 2025
PubMed
Summary
This summary is machine-generated.

Researchers identified a novel drug target for Alzheimer's disease (AD) treatment. The paired immunoglobulin-like receptor B (PirB) and its regulator LOTUS show potential for improving cognitive function and combating AD pathology.

More Related Videos

Quantitative Measurement of &#947;-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

6.9K
Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
06:19

Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model

Published on: October 20, 2023

2.2K

Related Experiment Videos

Last Updated: Sep 9, 2025

A Caenorhabditis elegans Model System for Amylopathy Study
10:33

A Caenorhabditis elegans Model System for Amylopathy Study

Published on: May 17, 2013

10.6K
Quantitative Measurement of &#947;-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
06:40

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

6.9K
Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
06:19

Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model

Published on: October 20, 2023

2.2K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) pathogenesis is extensively studied, yet effective treatments remain elusive.
  • Paired immunoglobulin-like receptor B (PirB) is a neuronal receptor implicated in regulating plasticity and responding to amyloid-beta (Aβ).

Purpose of the Study:

  • To explore PirB as a novel therapeutic target for AD.
  • To investigate the role of lateral olfactory tract usher substance (LOTUS) as an endogenous inhibitor of PirB and its potential in AD treatment.

Main Methods:

  • Review of existing research on PirB, LOTUS, and their roles in neuronal plasticity and Aβ pathology.
  • Analysis of PirB's function as an Aβ receptor and its impact on neuronal health.

Main Results:

  • PirB acts as a negative regulator of neuronal plasticity; its inhibition enhances plasticity, spine density, and cognitive function.
  • PirB functions as a receptor for Aβ, mediating neurotoxicity and reduced plasticity.
  • LOTUS, an endogenous antagonist of PirB, inhibits Aβ-induced neurotoxicity.

Conclusions:

  • PirB represents a promising, novel drug target for Alzheimer's disease.
  • LOTUS, by inhibiting PirB's Aβ receptor function, may offer therapeutic benefits against Aβ pathology.